Gyre Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

Rhea-AI Impact

(Low)

Rhea-AI Sentiment

(Neutral)

Rhea-AI Summary

Gyre Therapeutics (Nasdaq: GYRE), a commercial-stage biotech company focusing on chronic organ diseases, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. CEO Han Ying, PhD, will present a company overview on September 10, 2024, at 8:30 AM ET.

The presentation will be available via live webcast on Gyre's website Events and Presentations page. For those unable to attend the live session, a replay will be accessible afterward. This event provides an opportunity for investors to gain insights into Gyre's operations, clinical development programs, and future prospects in the biotechnology sector.

09/04/2024 - 04:05 PM

SAN DIEGO, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced that Han Ying, PhD, Chief Executive Officer, will be presenting a company overview at the H.C. Wainwright 26^th Annual Global Investment Conference on Tuesday, September 10, 2024, at 8:30 AM ET (5:30 AM PT).

The live webcast will be available on the Events and Presentations page of Gyre’s website. A webcast replay will be accessible following the live session.

About Gyre Therapeutics

Gyre Therapeutics is a biopharmaceutical company headquartered in San Diego, CA, with a primary focus on the development and commercialization of F351 (Hydronidone) for the treatment of NASH-associated fibrosis in the U.S. Gyre’s development strategy for F351 in NASH is based on the company’s experience in NASH rodent model mechanistic studies and CHB-induced liver fibrosis clinical studies. Gyre is also advancing a diverse pipeline in the PRC through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230.

For Investors:

Stephen Jasper

stephen@gilmartinir.com

FAQ

When is Gyre Therapeutics (GYRE) presenting at the H.C. Wainwright Global Investment Conference?

Gyre Therapeutics (GYRE) is presenting at the H.C. Wainwright 26th Annual Global Investment Conference on Tuesday, September 10, 2024, at 8:30 AM ET (5:30 AM PT).

Who will be presenting for Gyre Therapeutics (GYRE) at the investment conference?

Han Ying, PhD, the Chief Executive Officer of Gyre Therapeutics (GYRE), will be presenting a company overview at the conference.

How can investors access Gyre Therapeutics' (GYRE) presentation at the H.C. Wainwright conference?

Investors can access a live webcast of Gyre Therapeutics' (GYRE) presentation on the Events and Presentations page of the company's website. A replay will also be available after the live session.